Maribavir for Refractory Cytomegalovirus Infections With or Without Resistance Post-Transplant: Results form a Phase 3 Randomized Clinical Trial 
Date: August 25, 2022
Time: 2:00 PM (Eastern Standard Time)
Speakers:
Christina Connelly-Hooker, MSN, MBA, RN, CCM
Medical Science Liaison
Takeda
NO CE Available with this Webinar
Learning Objectives:
- Describe maribavir mechanism of action and its indication
- Review maribavir clinical data (SOLSTICE trial), including safety and efficacy